牛牛AI助理已提取核心訊息
On February 16, 2024, 180 Life Sciences Corp. filed a prospectus supplement with the SEC, updating and amending its previous prospectus dated February 9, 2024. The supplement includes information from the company's Current Report on Form 8-K and announces shareholder approval for the issuance of shares upon exercise of certain warrants. The warrants are now exercisable until February 16, 2029. Additionally, at a Special Meeting on the same day, stockholders approved a reverse stock split, an amendment to the company's Omnibus Incentive Plan, and the issuance of shares exceeding 19.99% of the outstanding common stock at a price below the Nasdaq minimum. The company's common stock and warrants are traded on the Nasdaq under the symbols 'ATNF' and 'ATNFW' respectively. The last reported sale price of the common stock was $0.21 per share on February 15, 2024.
On February 16, 2024, 180 Life Sciences Corp. filed a prospectus supplement with the SEC, updating and amending its previous prospectus dated February 9, 2024. The supplement includes information from the company's Current Report on Form 8-K and announces shareholder approval for the issuance of shares upon exercise of certain warrants. The warrants are now exercisable until February 16, 2029. Additionally, at a Special Meeting on the same day, stockholders approved a reverse stock split, an amendment to the company's Omnibus Incentive Plan, and the issuance of shares exceeding 19.99% of the outstanding common stock at a price below the Nasdaq minimum. The company's common stock and warrants are traded on the Nasdaq under the symbols 'ATNF' and 'ATNFW' respectively. The last reported sale price of the common stock was $0.21 per share on February 15, 2024.
2024年2月16日，180生命科學公司向美國證券交易委員會提交了招股說明書補充文件，更新並修改了其先前於2024年2月9日發佈的招股說明書。該補充文件包括公司8-K表最新報告中的信息，並宣佈股東批准在行使某些認股權證後發行股票。認股權證現在的有效期至2029年2月16日。此外，在當天的特別會議上，股東批准了反向股票拆分、公司綜合激勵計劃的修正案，以及以低於納斯達克最低價格的價格發行超過已發行普通股19.99％的股票。該公司的普通股和認股權證分別在納斯達克上市，股票代碼分別爲 “ATNF” 和 “ATNFW”。2024年2月15日，上次公佈的普通股銷售價格爲每股0.21美元。
2024年2月16日，180生命科學公司向美國證券交易委員會提交了招股說明書補充文件，更新並修改了其先前於2024年2月9日發佈的招股說明書。該補充文件包括公司8-K表最新報告中的信息，並宣佈股東批准在行使某些認股權證後發行股票。認股權證現在的有效期至2029年2月16日。此外，在當天的特別會議上，股東批准了反向股票拆分、公司綜合激勵計劃的修正案，以及以低於納斯達克最低價格的價格發行超過已發行普通股19.99％的股票。該公司的普通股和認股權證分別在納斯達克上市，股票代碼分別爲 “ATNF” 和 “ATNFW”。2024年2月15日，上次公佈的普通股銷售價格爲每股0.21美元。
有用
沒用